Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Brilinta

- PMLiVE

AZ/Merck & Co’s PARP inhibitor Lynparza scores trial win in early breast cancer

Trial halted early after crossing superiority boundary for the primary endpoint of invasive disease-free survival

- PMLiVE

Three strategies for managing loss of exclusivity successfully

Consultant, Claire Taylor explains why you should be strategically planning your LOE strategy years in advance.

Blue Latitude Health

- PMLiVE

WHO grants emergency use listing for AZ/Oxford University’s COVID-19 vaccine

The emergency use listing authorises the use of the vaccine in all adults, including over-65s

- PMLiVE

AZ/Oxford University’s COVID-19 vaccine to be evaluated in children and young adults

First study to assess the safety and immune response of the vaccine in children

- PMLiVE

AZ forecasts growth in 2021 after revenues surge in Q4

Most recent quarter is first 'for many years' in which product sales were in excess of $7bn

- PMLiVE

WHO backs AZ/Oxford COVID-19 vaccine, including in older adults

WHO's Sage panel also recommends a two-dose regimen given eight to 12 weeks apart

- PMLiVE

AZ partners with IDT Biologika to bolster manufacturing for COVID-19 vaccine in EU

AZ is looking to accelerate vaccine output in Q2 2021

- PMLiVE

NIH trial of AZ’s long-acting COVID-19 antibody launches in the US

Study will evaluate efficacy of drug in patients hospitalised with COVID-19

- PMLiVE

South Africa puts AZ/Oxford COVID-19 vaccine roll-out on hold

Pre-print study results found jab offers 'minimal' protection against B.1.351 variant

- PMLiVE

UK launches world-first COVID-19 study evaluating a mixed-vaccine regimen

Participants could receive AZ/Oxford University's vaccine for their first dose and Pfizer/BioNTech's vaccine for their second

- PMLiVE

EU may restrict exports of some COVID-19 vaccines

Proposed strategy follows a confrontation between the EU and AstraZeneca

- PMLiVE

The UK reasserts that the AZ vaccine is ‘effective across all age groups’

Germany's draft guidance does not recommend the vaccine for people over 65

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links